Specialty Pharmacy

New drug shows promising signs of delaying the development of existing breast and lung cancers. .

The triple combination includes a novel cystic fibrosis transmembrane conductance regulator amplifier, third generation corrector, and potentiator.

Pediatric patients treated with larotrectinib in a clinical trial demonstrated a 93% response rate.

An experimental program in Maryland aimed to reduce health care spending by shifting away from hospital-based care and toward less costly, primary, preventive, and outpatient services.

Top news of the day from across the health care landscape.

Upadacitinib met primary endpoints of ACR20 and clinical remission versus placebo in treatment of moderate to severe rheumatoid arthritis.

Pharmacists can help optimize medication regimens to produce the best patient outcomes at the lowest cost.

Physicians reported inaccurate self-perceptions when it came to opioid prescribing

Top news of the day from across the health care landscape.

Services such as Uber and Lyft that help get patients to their medical appointments could also bring patients to their pharmacies.

Rucaparib demonstrated statistically-significant improvement in progression-free survival for patients in the maintenance treatment setting.

Imraldi, a biosimilar referencing Humira, is expected to launch initially in Europe.

A novel chimera targets the growth factors responsible for certain types of breast cancer.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Alcohol-dependent patients with hepatitis C virus comorbidity found to have greater deficits in the frontal, precentral, superior, and orbital volumes.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The final rules clarifies several issues important to pharmacists and hints at further rule-making to address direct and indirect remuneration fees.

According to the study, patients who take a reduced dose of abiraterone with a low-fat meal may cut costs by as much as $300,000.

Top news of the day from across the health care landscape.

Smoking and obesity account for a significant number of cancers worldwide.

Commonwealth Fund researchers present ideas for increasing competition, applying value-based purchasing, and protecting patients from high out-of-pocket costs.

Researchers find that disputed bills amount to $54 billion annually across all health insurers.

Top news of the day from across the health care landscape.

Nivolumab plus ipilimumab demonstrated clinical benefit in previously treated patients with dMMR or MSI-H metastatic colorectal cancer.

Triple-negative and HER2-positive breast cancers may be unlikely to develop lymph node metastases.

The future affordability of health insurance coverage remains a concern for many Americans.

Innovative specialty drugs could result in more payers adopting value-based contracting.